{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:24:28Z","timestamp":1786951468591,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jdcr.2026.05.069","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:43:23Z","timestamp":1780760603000},"page":"129-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tofacitinib exposure across 2 pregnancies in alopecia universalis: Case report and literature review of Janus kinase inhibitors in pregnancy"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4671-010X","authenticated-orcid":false,"given":"Abdulmajeed","family":"Alajlan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4248-8312","authenticated-orcid":false,"given":"Naif Ahmed","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaiman","family":"Alfouzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maee","family":"Barakeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Alangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Alsuwaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2026.05.069_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2026.05.069_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jdv.19768","article-title":"European expert consensus statement on the systemic treatment of alopecia areata","volume":"38","author":"Rudnicka","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdcr.2026.05.069_bib3","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-020-01346-4","article-title":"Safety of new biologics (vedolizumab and ustekinumab) and small molecules (tofacitinib) during pregnancy: a review","volume":"80","author":"Gisbert","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jdcr.2026.05.069_bib4","series-title":"XELJANZ (tofacitinib) [package insert]","first-page":"52","year":"2018"},{"issue":"1","key":"10.1016\/j.jdcr.2026.05.069_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.14309\/ajg.0000000000003651","article-title":"Global consensus statement on the management of pregnancy in inflammatory bowel disease","volume":"121","author":"Mahadevan","year":"2026","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jdcr.2026.05.069_bib10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/bjd\/ljad279","article-title":"Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance","volume":"189","author":"Bergamini","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdcr.2026.05.069_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19899296","article-title":"Baricitinib exposure during pregnancy in rheumatoid arthritis","volume":"12","author":"Costanzo","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"10","key":"10.1016\/j.jdcr.2026.05.069_bib14","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/10428194.2024.2355558","article-title":"Successful pregnancy outcome in a patient with myelofibrosis receiving ruxolitinib treatment in the first trimester","volume":"65","author":"Urosevic","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jdcr.2026.05.069_bib15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/16078454.2020.1838708","article-title":"Etoposide combined with ruxolitinib for refractory hemophagocytic lymphohistiocytosis during pregnancy: a case report and literature review","volume":"24","author":"Wang","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.jdcr.2026.05.069_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cgh.2024.01.019","article-title":"Tofacitinib in pregnancy: assessing pregnancy and infant outcomes, cord blood, and breast milk concentrations","volume":"23","author":"Mitrova","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jdcr.2026.05.069_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40261-024-01353-3","article-title":"Experience of tofacitinib use in pregnancy in patients with ulcerative colitis","volume":"44","author":"Chaparro","year":"2024","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.jdcr.2026.05.069_bib16","article-title":"Normal infant immunologic assessment and uneventful live rotavirus vaccination despite continuous tofacitinib exposure in utero and during breastfeeding","volume":"6","author":"Ernest-Suarez","year":"2024","journal-title":"Crohns Colitis 360"},{"issue":"5","key":"10.1016\/j.jdcr.2026.05.069_bib17","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/ibd\/izae076","article-title":"Tofacitinib as a rescue therapy for ulcerative colitis in pregnancy","volume":"30","author":"Rowan","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.jdcr.2026.05.069_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.8764","article-title":"First-trimester exposure to tofacitinib in ulcerative colitis: a case report of a healthy newborn and literature review","volume":"12","author":"Arzivian","year":"2024","journal-title":"Clin Case Rep"},{"issue":"6","key":"10.1016\/j.jdcr.2026.05.069_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15209","article-title":"Pregnancy outcomes following tofacitinib use for synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: case report","volume":"27","author":"Zhang","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jdcr.2026.05.069_bib12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S2468-1253(23)00158-9","article-title":"Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis","volume":"8","author":"Julsgaard","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jdcr.2026.05.069_bib20","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/bdr2.1942","article-title":"Fetal exposure to tofacitinib during the first trimester: a healthy newborn case report","volume":"113","author":"Fern\u00e1ndez-S\u00e1nchez","year":"2021","journal-title":"Birth Defects Res"},{"issue":"8","key":"10.1016\/j.jdcr.2026.05.069_bib21","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf"},{"issue":"10","key":"10.1016\/j.jdcr.2026.05.069_bib9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40264-024-01454-0","article-title":"Pregnancy outcomes in patients treated with upadacitinib: analysis of data from clinical trials and postmarketing reports","volume":"47","author":"Mahadevan","year":"2024","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.jdcr.2026.05.069_bib23","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1111\/jdv.19557","article-title":"Pregnancy outcome of a patient treated with upadacitinib for severe atopic dermatitis","volume":"38","author":"Gargiulo","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.jdcr.2026.05.069_bib7","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626003462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626003462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:36:31Z","timestamp":1786948591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626003462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":21,"alternative-id":["S2352512626003462"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.05.069","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tofacitinib exposure across 2 pregnancies in alopecia universalis: Case report and literature review of Janus kinase inhibitors in pregnancy","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.05.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}